Stem Sellouts
By Jesse Reynolds,
TomPaine.com
| 07. 19. 2005
Recent developments—both technical and political —have once again brought stem cell research to the front pages of newspapers across the country. Sens. Tom Harkin, D-Iowa, and Arlen Specter, R-Pa., are the sponsors of a bill in the Senate that would largely undo President Bush’s restrictive federal funding policies. It’s already passed the House, and is scheduled for a Senate vote this month. But now conservatives are working to dilute support for it by introducing several competing bills that would fund stem cell research that does not destroy human embryos.
Progressives are inclined to react to these reports by strengthening their support of stem cell research as an effective wedge issue to split Republicans. But before we move ahead with simplistic calls for more funding and fewer restrictions, we should pay heed to troubles with California’s new stem cell research agency— and to the larger implications of biotech boosterism.
California’s Calamity
Last fall, Californians approved Proposition 71, which established the Institute for Regenerative Medicine to distribute $3 billion in stem cell research grants. Voters were swayed, with the help of a...
Related Articles
By Emma McDonald Kennedy
| 10.29.2026
At the beginning of Nathan Fielder and Lance Oppenheim’s blockbuster documentary You Can See Everything, Billy Evans (partner of Theranos founder and convicted fraudster Elizabeth Holmes), says that they decided to do the film for one purpose: “radical transparency.” As they work on “Theranos 2.0,” Evans and Holmes want to show the public that she has been misunderstood –– painted as a liar and a fraud in the public imagination (and the courts) despite, as she claims in the...
By Charles Schmidt, Undark | 09.25.2026
In 2010, scientists at the University of Tokyo and other institutions reported a startling achievement: They had successfully grown a pancreas made almost entirely of rat cells within the bodies of mice. The research was directed by Hiromitsu Nakauchi, a...
By Editors, Nature | 08.18.2026
Shinya Yamanaka doesn’t see himself as a celebrity. But people do recognize the stem-cell researcher when he’s out for a run, often while training for a marathon, on the streets of Kyoto, Japan.
Many of them call out words of...
By Jessica Hamzelou, MIT Technology Review | 07.30.2026
As of this week in Montana, any biotech company with an experimental drug has a clear path to selling it to consumers. Companies whose drugs have been through preliminary testing—sometimes in as few as 10 healthy people—can pay $12,500 to...